rHuPH20
Sponsors
Halozyme Therapeutics, Bristol-Myers Squibb, UMC Utrecht, Janssen Research & Development, LLC, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Advanced CancerCancerDermatitis, Allergic ContactDiabetes MellitusHIV AntibodiesHIV InfectionsHealthyHealthy Volunteers
Phase 1
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
CompletedNCT00803972
Start: 2008-11-30End: 2009-08-28Updated: 2018-08-15
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
CompletedNCT00807963
Start: 2008-12-31End: 2009-09-21Updated: 2018-08-15
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
CompletedNCT00862849
Start: 2009-03-31End: 2009-08-31Updated: 2014-07-22
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
CompletedNCT02754141
Start: 2016-06-21End: 2021-10-12Updated: 2023-04-05
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
CompletedNCT03320707
Start: 2017-10-16End: 2019-08-27Updated: 2025-02-03
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
TerminatedNCT03446040
Start: 2018-03-08End: 2024-08-29Updated: 2025-09-18
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
CompletedNCT03538626
Start: 2018-06-21End: 2022-08-29Updated: 2024-02-01
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
CompletedNCT03656718
Start: 2018-10-29End: 2024-09-12Updated: 2025-11-12
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
CompletedNCT03972306
Start: 2019-08-12End: 2025-06-03Updated: 2025-07-08
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
CompletedNCT04112498
Start: 2019-10-01End: 2023-02-27Updated: 2023-04-06
Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
CompletedNCT04920370
Start: 2019-09-04End: 2021-11-16Updated: 2022-02-11
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
CompletedNCT05291520
Start: 2022-02-23End: 2023-04-10Updated: 2024-09-19
Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
CompletedNCT05396742
Start: 2018-08-09End: 2019-05-21Updated: 2024-01-22
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RecruitingNCT05418868
Start: 2022-06-14End: 2027-06-08Target: 214Updated: 2025-12-18
First Time in Human Study of Long Acting VH4524184 Formulations
RecruitingNCT06310551
Start: 2024-03-21End: 2028-01-21Target: 268Updated: 2026-03-16
Phase 2
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
CompletedNCT00928447
Start: 2009-06-23End: 2009-09-13Updated: 2021-12-17
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Active, not recruitingNCT05996471
Start: 2023-08-17End: 2028-11-09Updated: 2026-03-11
Phase 3
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
CompletedNCT03735121
Start: 2018-12-27End: 2024-11-11Updated: 2025-12-05
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Active, not recruitingNCT05625399
Start: 2023-03-06End: 2027-11-18Updated: 2025-08-24
Unknown Phase
Related Papers
1 more papers not shown